AMGN
Amgen
$344.72
▲ 2.1%Updated Today 7:15 PM ET
▲ Up 16.6% over the last 12 months
Market Cap
$182.21B
P/E
23.51x
Forward P/E (est.)
17.91x
ROE
89.4%
Revenue Growth
9.1%
EPS Growth
31.3%
Profit Margin
21.0%
FCF Yield
6.0%
Debt / Equity
6.31x
ROIC
11.0%
Interest Coverage
—
Current Ratio
1.26x
Dividend Yield
2.9%
Implied Growth (rev. DCF)
4.4%
Rating Score
68/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what AMGN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. AMGN trades near $344.72, above its 50-day average ($340.26) and 200-day average ($331.88). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 51 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. AMGN's is $10.23 (~3.0% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month AMGN found buyers near $322.30 (support) and sellers near $358.46 (resistance); its 52-week range is $267.83–$391.29. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 2.7× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Amgen (AMGN) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $182.21B.
In its latest reported year it generated about $36.75B in revenue and $7.71B in net profit.
Our model rates AMGN Favorable (68/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
9.1%
Revenue moved from $25.98B in 2021 to $36.75B in 2025, a 9.1% compound annual growth rate. The most recent year grew a steady 9.1% year over year. Slower, mature growth is common for established businesses.
Gross Margin
74.0%
Operating Margin
24.7%
Net Margin
21.0%
ROE
89.4%
Amgen keeps about 21.0% of each sales dollar as net profit, with a 74.0% gross margin and 24.7% operating margin. Return on equity is 89.4% and return on invested capital about 11.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$57.32B
Net Debt
$45.28B
Net Debt / EBITDA
4.99x
Debt / Equity
6.31x
Leverage: debt-to-equity is 6.3x, with a current ratio of 1.3x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $57.32B of total debt against $12.04B of cash.
Operating CF
$9.96B
Free Cash Flow
$8.10B
FCF Margin
22.0%
In the latest year Amgen produced about $9.96B of operating cash flow and $8.10B of free cash flow after capital spending. That is a free-cash-flow yield of about 6.0% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
23.51x
P/S
5.14x
P/B
19.76x
EV / EBITDA
16.36x
AMGN trades at 23.5x trailing earnings (about 17.9x on estimated forward earnings), 5.1x sales, and 19.8x book value. Reverse-engineering today's price implies the market expects roughly 4.4% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How AMGN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), AMGN ranks #9 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (23.5x P/E vs. 25.4x median) with a higher return on equity (89.4% vs. 14.9%) and faster revenue growth (9.1% vs. 7.9%).
P/E vs sector
23.5x
median 25.4x
ROE vs sector
89.4%
median 14.9%
Growth vs sector
9.1%
median 7.9%
Sector rank
#9
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$308.03 – $528.05
vs. $344.72 today · expected CAGR -2% – 9%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $40.06B | $43.66B | $47.59B | $51.88B | $56.55B |
| Net income | $8.41B | $9.17B | $9.99B | $10.89B | $11.87B |
| EPS | $15.59 | $16.99 | $18.52 | $20.19 | $22.00 |
| Share price (low) | $218.21 | $237.85 | $259.26 | $282.59 | $308.03 |
| Share price (high) | $374.08 | $407.75 | $444.45 | $484.45 | $528.05 |
| CAGR (low–high) | -37% / 9% | -17% / 9% | -9% / 9% | -5% / 9% | -2% / 9% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for AMGN:
- High net margins (21.0%) point to pricing power or efficiency.
- Strong return on equity (89.4%) shows capital is put to work well.
- Healthy free-cash-flow yield (~6.0%) funds buybacks and dividends.
- Pays a 2.9% dividend on top of any price gains.
- Our model's overall read is Favorable (68/100).
The case against AMGN:
- Elevated leverage (debt/equity 6.3x) adds financial risk.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Balance-sheet risk — debt/equity of 6.3x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Amgen is a large-cap health care business growing at a mature pace, with solid profitability, and a heavier debt load to watch. It trades at 23.5x earnings, which our model scores Favorable (68/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.